NCNA – nucana plc - american depositary shares (US:NASDAQ)

News

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States
NuCana plc (NASDAQ: NCNA) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $150.00 to $25.00. They now have an "outperform" rating on the stock.
NuCana plc (NASDAQ: NCNA) was downgraded by analysts at William Blair from an "outperform" rating to a "market perform" rating.
NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com